A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3

PHASE2CompletedINTERVENTIONAL
Enrollment

167

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

May 31, 2014

Study Completion Date

April 30, 2015

Conditions
Cervical Intraepithelial Neoplasia
Interventions
BIOLOGICAL

VGX 3100

1ml of VGX-3100 delivered IM followed by electroporation at Day 0, Week 4 and Week 12.

BIOLOGICAL

Placebo

1ml of placebo delivered IM followed by electroporation at Day 0, Week 4 and Week 12.

DEVICE

CELLECTRA™-5P

CELLECTRA™-5P is used for electroporation following IM delivery of VGX 3100 or placebo on Day 0, Week 4 and Week 12.

Trial Locations (43)

3052

Victoria

6400

Batumi

7925

Cape Town

9301

Bloemfontein

10467

The Bronx

11777

Port Jefferson

19122

Philadelphia

21205

Baltimore

23233

Richmond

27103

Winston-Salem

27607

Raleigh

29572

Myrtle Beach

33316

Fort Lauderdale

33472

Boynton Beach

34231

Sarasota

43231

Columbus

48604

Saginaw

59808

Missoula

73117

Oklahoma City

80228

Lakewood

84062

Pleasant Grove

84070

Sandy City

84107

Murray

85015

Phoenix

85721

Tucson

90036

Los Angeles

91942

La Mesa

92324

Colton

97401

Eugene

98055

Renton

99207

Spokane

302017

Jaipur

411043

Pune

560017

Bangalore

H3A 1A1

Montreal

V5Z-1M9

Vancouver

Unknown

Tallinn

Tartu

Tbilisi

Kolkata

New Delhi

Seoul

00936

San Juan

Sponsors
All Listed Sponsors
lead

Inovio Pharmaceuticals

INDUSTRY

NCT01304524 - A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3 | Biotech Hunter | Biotech Hunter